Teva Says FTC Can't Draw It Into Pay-For-Delay Case

Law360, New York (January 8, 2014, 7:16 PM EST) -- Generic drug giant Teva Pharmaceutical Industries Ltd. on Wednesday urged a Pennsylvania federal judge to deny a bid from the Federal Trade Commission to add the company to its antitrust pay-for-delay suit against Provigil maker Cephalon Inc., arguing its acquisition of Cephalon is irrelevant to the case.

In an opposition to the FTC's motion to add Teva to its suit, the company told the court that the government was improperly attempting to ensure it could impose relief against Teva and its business operations if its case against...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

FEDERAL TRADE COMMISSION v. CEPHALON, INC.


Case Number

2:08-cv-02141

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Judge

MITCHELL S. GOLDBERG

Date Filed

May 8, 2008

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.